Company: TXG
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001770787-25-000051
Chunk: 66

Company: 10x Genomics, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 2
Chunk 66
---
 incurred net losses in each year. Our net income was $34.5 million and $0.2 million for the three and six months ended June 30, 2025 and net losses were $37.9 million and $97.8 million for the three and six months ended June 30, 2024, respectively. As of June 30, 2025, we had an accumulated deficit of $1.5 billion and cash and cash equivalents and marketable securities totaling $447.3 million. We expect to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term. 

19

Table of Contents

Comparison of the Three and Six Months Ended June 30, 2025 and 2024

Revenue

Three Months EndedJune 30,ChangeSix Months EndedJune 30,Change(dollars in thousands)20252024$%20252024$%InstrumentsChromium$5,727 $8,792 $(3,065)(35)%$11,640 $16,642 $(5,002)(30)%Spatial8,770 15,060 (6,290)(42)17,672 32,663 (14,991)(46)Total instruments revenue14,497 23,852 (9,355)(39)29,312 49,305 (19,993)(41)ConsumablesChromium85,788 94,108 (8,320)(9)169,897 178,035 (8,138)(5)Spatial36,397 29,254 7,143 24 67,644 55,662 11,982 22 Total consumables revenue122,185 123,362 (1,177)(1)237,541 233,697 3,844 2 Services8,475 5,776 2,699 47 16,127 10,993 5,134 47 Products and services revenue145,157 152,990 (7,833)(5)282,980 293,995 (11,015)(4)License and royalty revenue27,751 114 27,637 NM44,811 115 44,696 NMTotal revenue$172,908 $153,104 $19,804 13 %$327,791 $294,110 $33,681 11